DrugCite
Search

HYDROXYUREA

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Hydroxyurea Adverse Events Reported to the FDA Over Time

How are Hydroxyurea adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Hydroxyurea, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Hydroxyurea is flagged as the suspect drug causing the adverse event.

Most Common Hydroxyurea Adverse Events Reported to the FDA

What are the most common Hydroxyurea adverse events reported to the FDA?

Death
42 (1.39%)
Pyrexia
41 (1.36%)
Thrombocytopenia
41 (1.36%)
Pneumonia
40 (1.33%)
Asthenia
39 (1.29%)
Nausea
36 (1.19%)
Skin Ulcer
34 (1.13%)
Neoplasm Malignant
33 (1.09%)
Anaemia
31 (1.03%)
Headache
31 (1.03%)
Acute Myeloid Leukaemia
29 (.96%)
Show More Show More
Fatigue
25 (.83%)
Drug Ineffective
24 (.8%)
Sepsis
23 (.76%)
Leukopenia
22 (.73%)
Dizziness
21 (.7%)
Neutropenia
21 (.7%)
Disease Progression
20 (.66%)
Dyspnoea
20 (.66%)
Vomiting
18 (.6%)
White Blood Cell Count Decreased
18 (.6%)
Convulsion
17 (.56%)
Hypotension
17 (.56%)
Pancytopenia
17 (.56%)
Respiratory Failure
17 (.56%)
Fall
16 (.53%)
Haemoglobin Decreased
16 (.53%)
Leukocytosis
16 (.53%)
Confusional State
15 (.5%)
Dehydration
15 (.5%)
Malignant Neoplasm Progression
15 (.5%)
Chills
14 (.46%)
Epistaxis
14 (.46%)
Loss Of Consciousness
14 (.46%)
Malaise
14 (.46%)
Pain
14 (.46%)
Platelet Count Increased
14 (.46%)
Cardio-respiratory Arrest
13 (.43%)
Cerebral Haemorrhage
13 (.43%)
Diarrhoea
13 (.43%)
Myocardial Infarction
13 (.43%)
Drug Toxicity
12 (.4%)
Haemorrhage
12 (.4%)
Mucosal Inflammation
12 (.4%)
Pulmonary Embolism
12 (.4%)
Pulmonary Oedema
12 (.4%)
Tumour Lysis Syndrome
12 (.4%)
Drug Interaction
11 (.36%)
Thrombosis
11 (.36%)
Abdominal Pain
10 (.33%)
Bone Marrow Failure
10 (.33%)
Deep Vein Thrombosis
10 (.33%)
Febrile Neutropenia
10 (.33%)
General Physical Health Deteriorati...
10 (.33%)
Mental Status Changes
10 (.33%)
Myelofibrosis
10 (.33%)
Myocardial Ischaemia
10 (.33%)
Oedema Peripheral
10 (.33%)
Pericardial Effusion
10 (.33%)
Platelet Count Decreased
10 (.33%)
Renal Failure
10 (.33%)
Respiratory Distress
10 (.33%)
Weight Decreased
10 (.33%)
White Blood Cell Count Increased
10 (.33%)
Abdominal Pain Upper
9 (.3%)
Abortion Spontaneous
9 (.3%)
Arthralgia
9 (.3%)
Depression
9 (.3%)
Gastrointestinal Haemorrhage
9 (.3%)
Liver Function Test Abnormal
9 (.3%)
Tremor
9 (.3%)
Alanine Aminotransferase Increased
8 (.27%)
Brain Oedema
8 (.27%)
Cardiac Failure
8 (.27%)
Cytogenetic Analysis Abnormal
8 (.27%)
Drug Exposure During Pregnancy
8 (.27%)
Lethargy
8 (.27%)
Myelodysplastic Syndrome
8 (.27%)
Pleural Effusion
8 (.27%)
Pregnancy
8 (.27%)
Rash
8 (.27%)
Serum Ferritin Increased
8 (.27%)
Somnolence
8 (.27%)
Acute Myocardial Infarction
7 (.23%)
Anorexia
7 (.23%)
Arrhythmia
7 (.23%)
Ascites
7 (.23%)
Cholestasis
7 (.23%)
Condition Aggravated
7 (.23%)
Contusion
7 (.23%)
Cough
7 (.23%)
Drug Intolerance
7 (.23%)
Haematocrit Decreased
7 (.23%)
Hypertension
7 (.23%)
Hyponatraemia
7 (.23%)
Impaired Healing
7 (.23%)
Mouth Ulceration
7 (.23%)
Muscular Weakness
7 (.23%)
Mydriasis
7 (.23%)
Neoplasm Progression
7 (.23%)
Platelet Count Abnormal
7 (.23%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Hydroxyurea, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Hydroxyurea is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Hydroxyurea

What are the most common Hydroxyurea adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Hydroxyurea, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Hydroxyurea is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Hydroxyurea According to Those Reporting Adverse Events

Why are people taking Hydroxyurea, according to those reporting adverse events to the FDA?

Essential Thrombocythaemia
138
Chronic Myeloid Leukaemia
115
Sickle Cell Anaemia
85
Polycythaemia Vera
65
Glioblastoma Multiforme
38
Drug Use For Unknown Indication
33
Show More Show More
Product Used For Unknown Indication
31
Platelet Count Increased
31
Hiv Infection
24
Myeloproliferative Disorder
22
Thrombocytosis
21
Neoplasm Malignant
20
Thrombocythaemia
19
Acute Myeloid Leukaemia
19
Polycythaemia
18
Platelet Disorder
15
Leukocytosis
15
White Blood Cell Count Increased
8
Psoriasis
7
Myelofibrosis
7
Anaplastic Astrocytoma
7
Thrombocytopenia
7
Astrocytoma
6
Skin Ulcer
5
Pain
5
Head And Neck Cancer
5
Myelodysplastic Syndrome
4
Carcinoma
4
Anaemia
4
Leukaemia
4
Thrombosis Prophylaxis
3
Haematopoietic Neoplasm
3
Glioblastoma
3
Prophylaxis
3
Thalassaemia Beta
3
Myeloid Leukaemia
3
Splenomegaly
3
Tonsil Cancer
3
Antiretroviral Therapy
2
Platelet Count Decreased
2
Chronic Myelomonocytic Leukaemia
2
Therapeutic Procedure
2
Blood Disorder
2
Cerebrovascular Accident
2
Eosinophilic Leukaemia
2
Brain Neoplasm
2
Prostate Cancer
2
Squamous Cell Carcinoma
2
Acute Monocytic Leukaemia
2
Pustular Psoriasis
2
Stem Cell Transplant
2

Drug Labels

LabelLabelerEffective
HydroxyureaAmerican Health Packaging04-MAY-11
HydreaE.R. Squibb & Sons, L.L.C.26-JAN-12
DroxiaE.R. Squibb & Sons, L.L.C.26-JAN-12
HydroxyureaPar Pharmaceutical, Inc.16-FEB-12
HydroxyureaPhysicians Total Care, Inc.01-JUN-12
HydroxyureaBarr Laboratories Inc.10-AUG-12
HydroxyureaGolden State Medical Supply, Inc.15-OCT-12

Hydroxyurea Case Reports

What Hydroxyurea safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Hydroxyurea. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Hydroxyurea.